Search Result

Results for "

Oxaliplatin

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Antibiotic (2) Apoptosis (8) Autophagy (1) Bacterial (3) Bcl-2 Family (1) Cannabinoid Receptor (1) CXCR (1) DNA/RNA Synthesis (4) Drug Intermediate (1) FABP (1) Fungal (2) Gap Junction Protein (2) GPR84 (1) Histamine Receptor (1) Isotope-Labeled Compounds (1) mAChR (1) PARP (2) Sigma Receptor (1)
By Research Areas:	Cancer (12) Infection (3) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (4)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17371

*Oxaliplatin* Maximum Cited Publications 130 Publications Verification	DNA/RNA Synthesis Apoptosis	Cancer
Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research .

HY-W778423

[Pt(DACH)(OH)2(ox)] Dihydroxy Oxaliplatin-Pt(IV)	Drug Intermediate	Cancer
[Pt(DACH)(OH)2(ox)] is a Oxaliplatin (HY-17371)-based Pt(IV) scaffold. [Pt(DACH)(OH)2(ox)] reacts with N-hydroxysuccinimide (NHS) ester of PPA to yield phorbiplatin. Phorbiplatin is a highly potent Pt(IV) antitumor prodrug .

HY-159115

ART26.12	FABP Cannabinoid Receptor	Metabolic Disease
ART26.12 is an orally active FABP5 inhibitor with anti-cannabinoid properties. ART26.12 effectively prevents and alleviates Oxaliplatin (HY-17371)-induced pain through lipid modulation and cannabinoid receptor activation .

HY-17371R

Oxaliplatin (Standard)	DNA/RNA Synthesis Apoptosis	Cancer
Oxaliplatin (Standard) is the analytical standard of Oxaliplatin. This product is intended for research and analytical applications. Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research .

HY-17371S

Oxaliplatin-d10	Isotope-Labeled Compounds Apoptosis DNA/RNA Synthesis	Cancer
Oxaliplatin-d₁₀ is a deuterium labeled Oxaliplatin (HY-17371). Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research .

HY-17371A

(rel)-Oxaliplatin	DNA/RNA Synthesis Apoptosis	Cancer
(rel)-Oxaliplatin is a DNA synthesis inhibitor. (rel)-Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. (rel)-Oxaliplatin can be used for cancer research .

HY-163383

L-Ent-oxPt(IV) L-EOP	Bacterial	Infection
L-Ent-oxPt IV (L-EOP) is a Oxaliplatin (HY-17371)-based siderophore-platinum conjugate. L-Ent-oxPt IV exhibits selectivity towards Escherichia coli and antibacterial activity through DNA damage .

HY-124056

AZ10397767	CXCR	Cancer
AZ10397767 is an orally active, selective CXCR2 receptor antagonist with an IC₅₀ of 1 nM. AZ10397767 attenuates the Oxaliplatin (HY-17371)-induced NF-κB transcriptional activity and potentiates Oxaliplatin-induced apoptosis in androgen-independent prostate cancer (AIPC) cells. AZ10397767 significantly inhibits neutrophil recruitment into tumors which then adversely affects tumor growth in vitro and in vivo .

HY-108238

BSI-401	PARP	Cancer
BSI-401 is an orally active PARP-1 inhibitor. BSI-401 alone and in synergism with Oxaliplatin (HY-17371) inhibits pancreatic cancer .

HY-105253

PARP-2/1-IN-2	PARP	Neurological Disease
PARP-2/1-IN-2 (Compound 4a), the enantiomer of Veliparib (HY-10129), is a potent PARP inhibitor with K_is of 2 and 5 nM against PARP-2 and PARP-1, respectively. PARP-2/1-IN-2 has an EC₅₀ of 3 nM in a cell based assay of PARP activity .

HY-17409

Nystatin 30+ Cited Publications	Fungal Antibiotic Apoptosis Bacterial	Infection Cancer
Nystatin is an orally active polyene antifungal antibiotic effective against yeast and mycoplasma. Nystatin increases the permeability of plasma membranes to small monovalent ions, including chloridion . Nystatin is a cholesterol-sequestering agent , partially prevents Oxaliplatin-induced lipid raft aggregation, DR4 and DR5 clustering, and thereby reduces apoptosis .

HY-P9991A

Osemitamab (FUT8-KO)	Gap Junction Protein	Cancer
Osemitamab (FUT8-KO) is an anti-claudin-18.2 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .

HY-170444

ADS1017	Histamine Receptor mAChR	Neurological Disease
ADS1017 is the antagonist for histamine receptor and muscarinic receptor, that exhibits good affinities to hH3R, hH4R, hM2R and hM4R with pK_i of 6.8, 5.5, 7.4 and 7.2. ADS1017 exhibits analgesic and anti-allodynic efficacy in mice Capsaicin (HY-10448)-or Oxaliplatin (HY-17371)-induced pain models .

HY-17409R

Nystatin (Standard)	Fungal Antibiotic Apoptosis Bacterial	Infection
Nystatin (Standard) is the analytical standard of Nystatin. This product is intended for research and analytical applications. Nystatin is an orally active polyene antifungal antibiotic effective against yeast and mycoplasma. Nystatin increases the permeability of plasma membranes to small monovalent ions, including chloridion . Nystatin is a cholesterol-sequestering agent , partially prevents Oxaliplatin-induced lipid raft aggregation, DR4 and DR5 clustering, and thereby reduces apoptosis .

HY-P9991

Osemitamab TST001	Gap Junction Protein	Cancer
Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .

HY-161682

GPR84 antagonist 9	GPR84	Neurological Disease
GPR84 antagonist 9 (compound 320) is an orally active GPR84 antagonist with the IC₅₀ of 0.012 μM. GPR84 antagonist 9 can be used for study of inflammatory-driven pain diseases .

HY-164468

Ch282-5	Bcl-2 Family Apoptosis Autophagy	Cancer
Ch282-5 is an orally active inhibitor targeting the Bcl-2 protein, inducing mitochondria-dependent apoptosis (Apoptosis) by disrupting mitophagy and the mTOR pathway. Ch282-5 exhibits antiproliferative activity against colorectal cancer cells both in vitro and in vivo, and it also inhibits metastasis. Additionally, Ch282-5 enhances Oxaliplatin (HY-17371)-induced autophagy (Autophagy) by downregulating the Mcl-1 protein and increasing platelet count, alleviating adverse effects of Navitoclax (HY-10087) .

HY-160421

TREM2-IN-1	Apoptosis	Inflammation/Immunology Cancer
TREM2-IN-1 (OPA) is a TREM2 inhibitor derived from oxaliplatin and artesunate. TREM2-IN-1 can relieves immunosuppressive tumor microenvironment and enhancing chemical anticancer efficiency. TREM2-IN-1 deters the tumor growth in mice models bearing MC38 colorectal tumor by reducing the number of CD206 ⁺ and CX₃CR1 ⁺ immunosuppressive macrophages. TREM2-IN-1 also promotes the expansion and infiltration of immunostimulatory dendritic, cytotoxic T and natural killer cells .

HY-18099

S1RA 2 Publications Verification E-52862	Sigma Receptor 5-HT Receptor	Neurological Disease
S1RA (E-52862) is a highly selective σ1 receptor (σ1R) antagonist with K_is of 17 nM and 23.5 nM for human σ1R and guinea pig σ1R, respectively. S1RA has Moderate antagonistic activity for human 5-HT_2B receptor (K_i= 328 nM). S1RA has antinociceptive effects in neuropathic pain models. S1RA prevents mechanical and cold hypersensitivity in Oxaliplatin (HY-17371)-treated mice .

Cat. No.	Product Name	Target	Research Area

HY-P9991

Osemitamab TST001	Gap Junction Protein	Cancer
Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .

HY-P9991A

Osemitamab (FUT8-KO)	Gap Junction Protein	Cancer
Osemitamab (FUT8-KO) is an anti-claudin-18.2 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-17409

Nystatin 30+ Cited Publications	Infection Structural Classification Microorganisms Antifungal Macrolide Antibiotics Classification of Application Fields Antibiotics Source classification Mammalian Cell Culture Disease Research Disease Research Fields	Fungal Antibiotic Apoptosis Bacterial
Nystatin is an orally active polyene antifungal antibiotic effective against yeast and mycoplasma. Nystatin increases the permeability of plasma membranes to small monovalent ions, including chloridion . Nystatin is a cholesterol-sequestering agent , partially prevents Oxaliplatin-induced lipid raft aggregation, DR4 and DR5 clustering, and thereby reduces apoptosis .

HY-17409R

Nystatin (Standard)	Structural Classification Microorganisms Antifungal Macrolide Antibiotics Antibiotics Source classification Mammalian Cell Culture Disease Research	Fungal Antibiotic Apoptosis Bacterial
Nystatin (Standard) is the analytical standard of Nystatin. This product is intended for research and analytical applications. Nystatin is an orally active polyene antifungal antibiotic effective against yeast and mycoplasma. Nystatin increases the permeability of plasma membranes to small monovalent ions, including chloridion . Nystatin is a cholesterol-sequestering agent , partially prevents Oxaliplatin-induced lipid raft aggregation, DR4 and DR5 clustering, and thereby reduces apoptosis .

Cat. No.	Product Name	Chemical Structure

HY-17371S

Oxaliplatin-d10
Oxaliplatin-d₁₀ is a deuterium labeled Oxaliplatin (HY-17371). Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Oxaliplatin

Inhibitors & Agonists

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products